Cargando…

Metronomic vinorelbine is an excellent and safe treatment for advanced breast cancer: a retrospective, observational study

Advanced breast cancer (ABC) has become a chronic disease. In such a situation, an effective therapy with low toxicities and economically acceptable is needed. Metronomic vinorelbine (mVNR) has been proved to be effective on the control of MBC. The aim of this study is to evaluate the efficacy and s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Chien-Ting, Hsieh, Meng-Che, Su, Yu-Li, Hung, Chaio-Ming, Pei, Sung-Nan, Liao, Chun-Kai, Tsai, Yu-Fen, Liao, Hsiu-Yun, Liu, Wei-Ching, Chiu, Chong-Chi, Wu, Shih-Chung, Wang, Shih-Ho, Wei, Ching-Ting, Rau, Kun-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317530/ https://www.ncbi.nlm.nih.gov/pubmed/34335952 http://dx.doi.org/10.7150/jca.60682

Ejemplares similares

Enhanced antitumor and anti-angiogenic effects of metronomic Vinorelbine combined with Endostar on Lewis lung carcinoma
por: Qin, Rong-Sheng, et al.
Publicado: (2018)

Enhanced Paclitaxel Efficacy to Suppress Triple-Negative Breast Cancer Progression Using Metronomic Chemotherapy with a Controlled Release System of Electrospun Poly-d-l-Lactide-Co-Glycolide (PLGA) Nanofibers
por: Hsu, Ming-Yi, et al.
Publicado: (2021)

A Novel Combination of Bevacizumab with Chemotherapy Improves Therapeutic Effects for Advanced Biliary Tract Cancer: A Retrospective, Observational Study
por: Pei, Sung-Nan, et al.
Publicado: (2021)

Anti-tumor effects of low-dose metronomic vinorelbine in combination with alpelisib in breast cancer cells
por: Krajnak, Slavomir, et al.
Publicado: (2023)

S-1 versus Doublet Regimens as Adjuvant Chemotherapy in Patients with Advanced Gastric Cancer after Radical Surgery with D2 Dissection—A Propensity Score Matching Analysis
por: Hsieh, Meng-Che, et al.
Publicado: (2020)

Cellular and molecular effects of metronomic vinorelbine and 4-O-deacetylvinorelbine on human umbilical vein endothelial cells
por: Biziota, Eirini, et al.
Publicado: (2016)

An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer
por: Pujol, Jean-Louis, et al.
Publicado: (2019)

Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience
por: Rossi, David
Publicado: (2020)

Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine – a Phase I trial
por: Guetz, Sylvia, et al.
Publicado: (2017)

The Overall Efficacy and Outcomes of Metronomic Tegafur-Uracil Chemotherapy on Locally Advanced Head and Neck Squamous Cell Carcinoma: A Real-World Cohort Experience
por: Yeh, Tsung-Jang, et al.
Publicado: (2021)

Dysarthria Speech Detection Using Convolutional Neural Networks with Gated Recurrent Unit
por: Shih, Dong-Her, et al.
Publicado: (2022)

Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis
por: Gebbia, Vittorio, et al.
Publicado: (2020)

Durable Effect of Pyrotinib and Metronomic Vinorelbine in HER2-Positive Breast Cancer With Leptomeningeal Disease: A Case Report and Literature Review
por: Chi, Yajing, et al.
Publicado: (2022)

Excellent response to oral Metronomic chemotherapy in unresectable adenocarcinoma of external auditory canal
por: Noronha, Vanita, et al.
Publicado: (2015)

Management of cancer-related fatigue in Taiwan: an evidence-based consensus for screening, assessment and treatment
por: Rau, Kun-Ming, et al.
Publicado: (2022)

Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells
por: Chan, Tze-Sian, et al.
Publicado: (2016)

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study
por: Briasoulis, Evangelos, et al.
Publicado: (2013)

Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer
por: D'Ascanio, Michela, et al.
Publicado: (2018)

Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial
por: Wang, Zijing, et al.
Publicado: (2021)

Prevalence, risk factors, and optimized management of moderate-to-severe thirst in the post-anesthesia care unit
por: Lee, Chia-Wei, et al.
Publicado: (2020)

Correction: Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells
por: Chan, Tze-Sian, et al.
Publicado: (2023)

The implementation results of safe bicycle transport in Taipei City
por: Yin-Huan, Wu, et al.
Publicado: (2019)

Vinorelbine Augments Radiotherapy in Hepatocellular Carcinoma
por: Yeoh, Kheng Wei, et al.
Publicado: (2020)

Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study
por: Cerrito, Maria Grazia, et al.
Publicado: (2018)

Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients
por: Barlesi, Fabrice, et al.
Publicado: (2017)

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer
por: Chai, Yue, et al.
Publicado: (2023)

The Clinical Correlation of Regulatory T Cells and Cyclic Adenosine Monophosphate in Enterovirus 71 Infection
por: Wang, Shih-Min, et al.
Publicado: (2014)

An app for predicting nurse intention to quit the job using artificial neural networks (ANNs) in Microsoft Excel
por: Chen, Hsiu-Chin, et al.
Publicado: (2022)

ChemoSensitivity Assay Guided Metronomic Chemotherapy Is Safe and Effective for Treating Advanced Pancreatic Cancer
por: Isacoff, William H., et al.
Publicado: (2022)

Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study
por: Cazzaniga, M. E., et al.
Publicado: (2014)

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
por: Adamo, Barbara, et al.
Publicado: (2019)

Differences in N loading affect DOM dynamics during typhoon events in a forested mountainous catchment
por: Yeh, Tz-Ching, et al.
Publicado: (2019)

Excellence and safety in surgery require excellent and safe tutoring
por: Ferrarese, Alessia, et al.
Publicado: (2016)

Sex hormone‐binding globulin (SHBG) is a potential early diagnostic biomarker for gastric cancer
por: Cheng, Chao‐Wen, et al.
Publicado: (2017)

Dickkopf-1 Acts as a Profibrotic Mediator in Progressive Chronic Kidney Disease
por: Hsu, Yung-Chien, et al.
Publicado: (2023)

Immunophenotype Expressions and Cytokine Profiles of Influenza A H1N1 Virus Infection in Pediatric Patients in 2009
por: Wang, Shih-Min, et al.
Publicado: (2014)

Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study
por: Pepe, F. F., et al.
Publicado: (2022)

Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)
por: Camerini, Andrea, et al.
Publicado: (2015)

Metronomic vinorelbine: Anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition
por: MAVROEIDIS, L., et al.
Publicado: (2015)

MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors
por: Vicier, C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jqe6lnjn2inodbleg5ohge8e13